The Latest Breaking News from FDA

Mark Cuban’s prescription drug company, known for “cutting out the middle man,” is in conversations with hospitals around the nation to identify the most common drug shortages.

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

The free service from Field Trip Health is open to "anyone who's facing headwinds right now."

With the October inflation report showing signs of cooling and anticipations of a slowdown in interest rate hikes, the stock market looks poised to extend its recent rally. Hence, it could be wise to invest in fundamentally sound stocks Pfizer (PFE), Cisco Systems (CSCO), and Raytheon Technologies (RTX) that still…

The FDA will soon decide whether to approve Eisai's experimental drug lecanemab.

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out

Two deaths linked to the drug may present a more complicated path to approval.

The advent of vaping revived nicotine addiction among young people after a dramatic decline. The FDA seems poised to at last yank some products aimed at teens from the market. Will it work?

Amid prevalent COVID-19 cases, vaccine pioneer Pfizer (PFE) is significantly benefiting. Moreover, the company beat wall street expectations in the third quarter with a robust financial result and raised its revenue and EPS guidance for the year. Given its strong fundamentals, the stock could be a wise addition to your…